Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 March 2022 | Story NONSINDISO QWABE | Photo Supplied
Dr Ralph Clarke
Dr Ralph Clark, Director of the Afromontane Research Unit.

The African Mountain Research Foundation (AMRF), in association with the Afromontane Research Unit (ARU) of the University of the Free State (UFS), and the Global Mountain Safeguard Research Programme (GLOMOS), is hosting the first-ever Southern African Mountain Conference (SAMC2022). The theme of the conference is Southern African Mountains – their value and vulnerabilities.

The conference will bring relevant people together into one space for networking and information sharing, leading to more robust regional and international collaborations and comparative mountain studies with an increase in research activities, student capacity, researcher capacity and academic outputs that feed into policy and action. 

The conference will take place from 14 to 17 March 2022 in the majestic Maloti-Drakensberg Mountains in South Africa and Lesotho. 

According to the SAMC2022 website, this is a truly Southern African regional mountain conference, targeting the African region south of the Congo rainforest (DRC) and Lake Rukwa (Tanzania), but including Madagascar, the Comoros and the Mascarenes (i.e., Angola, the Comoros, the Democratic Republic of the Congo [southern mountains], Eswatini, Lesotho, Madagascar, Malawi, Mauritius, Mozambique, Namibia, La Réunion, South Africa, southern Tanzania, Zambia, and Zimbabwe).

Dr Ralph Clark, ARU Director, said the conference would be a high-level international event with UNESCO patronage and very valuable sponsors.

“The programme will have six parallel tracks (one being dedicated to postgraduate students), with about 200 papers being delivered. In addition, we have some very high-profile special sessions, such as an MRI special session on long-term monitoring activities and associated data availability for climate change-related applications across Africa’s mountains, as well as a UNESCO special session on regional collaboration. We also have Prof Julian Bayliss, described as the man who discovered an unseen world, as the guest speaker at the closing event.”

The conference will bring together relevant people in one space for networking and information sharing, leading to more robust regional and international collaborations and comparative mountain studies, with an increase in research activities, student capacity, researcher capacity, and academic outputs that feed into policy and action.

The GLOMOS team, one of the long-term partners of the ARU, spent the week of 8 to 11 March 2022 on the Qwaqwa Campus to strengthen collaboration and pave the way for new research opportunities in Phuthaditjhaba and the Maloti-Drakensberg.
GLOMOS represents an interface between the United Nations University Institute for Environment and Human Security (UNU-EHS) and Eurac Research. Postdoctoral fellow, Dr Stefano Terzi, said: “It’s very interesting for us to look at the Maloti-Drakensberg area because of its diversity. We are in the process of really exciting collaborations.”
Their projects include an understanding of the root causes of land degradation and improving decision-making processes for current water management within the context of water scarcity in the Maloti-Drakensberg.
• For more information on the speakers and the programme, click here 


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept